JP2023509484A5 - - Google Patents
Info
- Publication number
- JP2023509484A5 JP2023509484A5 JP2022541634A JP2022541634A JP2023509484A5 JP 2023509484 A5 JP2023509484 A5 JP 2023509484A5 JP 2022541634 A JP2022541634 A JP 2022541634A JP 2022541634 A JP2022541634 A JP 2022541634A JP 2023509484 A5 JP2023509484 A5 JP 2023509484A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- disorder
- substance
- dextromethadone
- administering
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026000511A JP2026062924A (ja) | 2020-01-03 | 2026-01-05 | 神経精神障害及び疾患のための疾患修飾処置としてのデキストロメサドン |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062956839P | 2020-01-03 | 2020-01-03 | |
| US62/956,839 | 2020-01-03 | ||
| US202062963874P | 2020-01-21 | 2020-01-21 | |
| US62/963,874 | 2020-01-21 | ||
| US202062993188P | 2020-03-23 | 2020-03-23 | |
| US62/993,188 | 2020-03-23 | ||
| US202063010391P | 2020-04-15 | 2020-04-15 | |
| US63/010,391 | 2020-04-15 | ||
| US202063031785P | 2020-05-29 | 2020-05-29 | |
| US63/031,785 | 2020-05-29 | ||
| PCT/US2020/067498 WO2021138443A1 (en) | 2020-01-03 | 2020-12-30 | Dextromethadone as a disease-modifying treatment for neuropsychiatric disorders and diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026000511A Division JP2026062924A (ja) | 2020-01-03 | 2026-01-05 | 神経精神障害及び疾患のための疾患修飾処置としてのデキストロメサドン |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023509484A JP2023509484A (ja) | 2023-03-08 |
| JP2023509484A5 true JP2023509484A5 (https=) | 2024-02-05 |
Family
ID=76687448
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022541634A Pending JP2023509484A (ja) | 2020-01-03 | 2020-12-30 | 神経精神障害及び疾患のための疾患修飾処置としてのデキストロメサドン |
| JP2026000511A Pending JP2026062924A (ja) | 2020-01-03 | 2026-01-05 | 神経精神障害及び疾患のための疾患修飾処置としてのデキストロメサドン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026000511A Pending JP2026062924A (ja) | 2020-01-03 | 2026-01-05 | 神経精神障害及び疾患のための疾患修飾処置としてのデキストロメサドン |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230017786A1 (https=) |
| EP (1) | EP4085044A4 (https=) |
| JP (2) | JP2023509484A (https=) |
| KR (1) | KR20220164470A (https=) |
| CN (1) | CN115397804A (https=) |
| AU (1) | AU2020419181A1 (https=) |
| BR (1) | BR112022013160A2 (https=) |
| CA (1) | CA3166254A1 (https=) |
| MX (1) | MX2022007768A (https=) |
| TW (1) | TW202140415A (https=) |
| UY (1) | UY39007A (https=) |
| WO (1) | WO2021138443A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119202724B (zh) * | 2024-09-25 | 2025-05-30 | 宁夏医科大学总医院 | 一种脓毒症心肌病诊断模型的构建方法及诊断系统 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1715843A1 (en) * | 2004-01-29 | 2006-11-02 | Neuromolecular Inc. | Combination of a nmda receptor antagonist and a mao-inhibitor or a gadph-inhibitor for the treatment of central nervous system-related conditions |
| US20100151014A1 (en) * | 2008-12-16 | 2010-06-17 | Alpharma Pharmaceuticals, Llc | Pharmaceutical composition |
| US9468611B2 (en) * | 2012-09-27 | 2016-10-18 | Relmada Therapeutics, Inc. | d-Methadone for the treatment of psychiatric symptoms |
| EP2906202A4 (en) * | 2012-10-15 | 2016-04-27 | Isa Odidi | ORAL DRUG RELIEF FORMULATIONS |
| AU2018215056A1 (en) * | 2017-01-31 | 2019-08-08 | Charles E. Inturrisi | D-methadone and its derivatives for use in the treatment of disorders of the nervous system |
| CA3064846A1 (en) * | 2017-05-25 | 2018-11-29 | Glytech, Llc | Combined therapy for nmdar antagonist-responsive neuropsychiatric disorders |
| EP3917619A4 (en) * | 2019-01-30 | 2022-10-26 | University of Padova | Structurally modified opioids for prevention and treatment of diseases and conditions |
-
2020
- 2020-12-30 KR KR1020227026586A patent/KR20220164470A/ko active Pending
- 2020-12-30 US US17/787,608 patent/US20230017786A1/en active Pending
- 2020-12-30 JP JP2022541634A patent/JP2023509484A/ja active Pending
- 2020-12-30 WO PCT/US2020/067498 patent/WO2021138443A1/en not_active Ceased
- 2020-12-30 BR BR112022013160A patent/BR112022013160A2/pt unknown
- 2020-12-30 MX MX2022007768A patent/MX2022007768A/es unknown
- 2020-12-30 EP EP20908770.9A patent/EP4085044A4/en active Pending
- 2020-12-30 AU AU2020419181A patent/AU2020419181A1/en active Pending
- 2020-12-30 CA CA3166254A patent/CA3166254A1/en active Pending
- 2020-12-30 CN CN202080097944.9A patent/CN115397804A/zh active Pending
-
2021
- 2021-01-04 TW TW110100157A patent/TW202140415A/zh unknown
- 2021-01-05 UY UY0001039007A patent/UY39007A/es unknown
-
2026
- 2026-01-05 JP JP2026000511A patent/JP2026062924A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Molinuevo et al. | Memantine: targeting glutamate excitotoxicity in Alzheimer's disease and other dementias | |
| JP7265990B2 (ja) | 神経変性疾患あるいは認知機能障害の予防または治療剤としてのｒ－ケタミンおよびその誘導体 | |
| JP6466540B2 (ja) | 多発性硬化症を治療するためのＰＰＡＲγアゴニスト | |
| JP2009511618A (ja) | 中度から重度のむずむず脚症候群（ｒｌｓ）を治療するためのプラミペキソールの使用 | |
| CN103974712A (zh) | 治疗阿尔茨海默氏症、亨廷顿氏症、孤独症和其他障碍的方法 | |
| Steiner et al. | The efficacy of fluoxetine in improving physical symptoms associated with premenstrual dysphoric disorder | |
| JP2024050575A (ja) | Ｌ－４－クロロキヌレニンの治療的使用 | |
| Catena-Dell'Osso et al. | Glutamate system as target for development of novel antidepressants | |
| CN114727989A (zh) | Gaba-a受体正变构调节剂与nmda拮抗剂、nmda负变构调节剂或nmda部分激动剂的组合 | |
| CN1104241C (zh) | 1－(2－萘－2－基乙基)－4－(3－三氟甲基苯基)－1,2,3,6－四氢吡啶用于制备治疗肌萎缩性脊髓侧索硬化的药物的用途 | |
| JP2023509484A5 (https=) | ||
| Junghanns et al. | Switching and combining of dopamine agonists | |
| CN105848655B (zh) | 用于注意力和认知障碍的、以及用于与神经变性障碍相关联的痴呆的新疗法 | |
| JP2018199736A (ja) | 神経変性障害を処置するための方法 | |
| JP2023504731A (ja) | タウオパチーを処置するためのペプチド組成物及び方法 | |
| WO2019171332A1 (en) | Treatment of demyelinating diseases | |
| CN1300217A (zh) | 瑞波西汀与吲哚洛尔的新的药物组合 | |
| US11318142B2 (en) | Pharmaceutical formulation for use in the treatment of depressive and anxiety disorders | |
| CN1917864A (zh) | 钠通道阻滞剂和选择性5－羟色胺摄取抑制剂的药物组合物 | |
| CN115835862A (zh) | 治疗阿尔茨海默病的组合及其应用 | |
| WO2021010348A1 (ja) | うつ病またはうつ症状の予防または治療剤としてのトランスフォーミング増殖因子β１ | |
| CN1105560C (zh) | 依法克生用于制备治疗亨廷顿舞蹈病的药物的应用 | |
| WO2017209027A1 (ja) | オートファジー誘導剤 | |
| Lin et al. | Perspective Chapter: NMDA | |
| JP2025503649A5 (https=) |